NewAmsterdam Pharma Company NAMS Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $457.61M-6.6% | $490M-9.0% | $538.41M-4.5% | $563.86M-24.7% | $748.42M-3.0% | ||
| $178.5M+22.1% | $146.24M-11.1% | $164.54M-6.1% | $175.3M+192% | $60.06M-3.8% | ||
| $658.04M-2.6% | $675.7M-7.7% | $732.33M-4.9% | $769.85M-5.8% | $817.3M-5.3% | ||
| $379K-1.0% | $383K+18.6% | $323K+3.5% | $312K+31.1% | $238K-1.7% | ||
| $375K-7.9% | $407K-7.3% | $439K-6.6% | $470K-6.4% | $502K-6.0% | ||
| $732.64M-4.8% | $769.28M-2.2% | $786.43M-3.5% | $815.11M-0.4% | $818.41M-5.3% | ||
| $8.09M-9.8% | $8.97M+147% | $3.63M-38.4% | $5.9M-3.2% | $6.09M+28.3% | ||
| $3.99M0.0% | $3.99M— | —— | —— | $3.03M-49.6% | ||
| $67.42M-21.4% | $85.79M+47.2% | $58.27M+59.6% | $36.51M-10.8% | $40.91M-61.7% | ||
| $67.42M-21.5% | $85.85M+47.1% | $58.36M+59.4% | $36.62M-10.8% | $41.05M-61.7% | ||
| $14.59M+2.2% | $14.28M+1.2% | $14.11M+0.7% | $14.01M+0.3% | $13.97M+3.9% | ||
| -$810.83M-6.4% | -$762.39M-10.9% | -$687.47M-11.7% | -$615.46M-2.9% | -$598.1M-7.1% | ||
| $665.22M-2.7% | $683.43M-6.1% | $728.07M-6.5% | $778.5M+0.1% | $777.36M+2.6% | ||
| $732.64M-4.8% | $769.28M-2.2% | $786.43M-3.5% | $815.11M-0.4% | $818.41M-5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can NewAmsterdam Pharma Company cover its short-term obligations?
- Its current ratio is 9.76 — current assets exceed current liabilities.
- Where does NewAmsterdam Pharma Company's balance sheet data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.